AVEO - 3 Things In Biotech August 15: Motif Looks To Advance A Safer Antibiotic For Skin Infection
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
AVEO partner moves forward with a HER3 treatment in China
Company: CANbridge Life Sciences and partner AVEO Pharmaceuticals (AVEO)
Therapy: CAN017
Disease: Esophageal squamous cell cancer
News: AVEO announced that the Chinese National Drug Administration has approved their IND to initiate clinical study of AVEO's HER3 antibody CAN017 in patients with esophageal squamous cell cancer. AVEO received a $2 million milestone payment